Ongoing 01 Jun 2025

Optimapharm - ADELA study

Enquire

Trial overview

Disease

Breast cancer

Topic

Interventional

Sponsor

MedSIR

Description

A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors. (The ADELA Study)

Study details

For detailed information on this trial, please click here

Trial status

Opening June 2025

Location

Oxford

Principal Investigator

Dr Mark Tuthill

MBBS BSc PhD FRCP

Consultant Medical Oncologist